Magnetic resonance imaging (MRI) really makes a difference when studying men who’ve had a negative prostate biopsy, but their prostate-specific antigen goes up overtime or something changes and there’s a continuing concern for prostate cancer, said Christopher Kane, MD, professor of urology, University of California, San Diego.
Magnetic resonance imaging (MRI) really makes a difference when studying men who’ve had a negative prostate biopsy, but their prostate-specific antigen goes up overtime or something changes and we think there’s a continuing concern for prostate cancer, said Christopher Kane, MD, professor of urology, University of California, San Diego.
Transcript (slightly modified)
How is MRI influencing prostate cancer diagnosis?
I think magnetic resonance imaging (MRI) has been 1 of the big changes over the last 5 years. The first place that MRI really makes a difference is in studying men who’ve had previous prostate biopsy, and that biopsy was negative, and overtime their prostate-specific antigen (PSA) goes up or something changes and we think there’s a continuing concern for prostate cancer. Now, we routinely do an MRI before we do a repeat biopsy, and if we see regions that are suspicious for high-grade prostate cancer, we adjust the biopsy to make sure we hit those regions, and that’s called targeted biopsy. That very much improves the outcome of repeat prostate biopsy.
So, we’ve known that and it’s been in our guidelines for more than 5 years, and what’s technology, and now we’re wondering, “Gee, if I have a man and we’re going to recommend a prostate biopsy based on PSA or family history or rectal exam, shouldn’t we do an MRI prior to similarly improve the performance of our biopsy?”
I think many of our programs that are using MRI more liberally are wondering whether we can improve the performance of the initial prostate biopsy by doing an MRI, and that’s an area of controversy not yet in the guidelines. The big controversy is that if we do this is that we’re going to increase costs of the screening episode, and is that justified by the marginal improvement in diagnostics.
That’s the subject of a number of clinical trials. It was the subject of the session this morning. A debate between Professor Emberton and Dr Pedrosa about where is MRI moving, and I think 1 of the places it’s likely moving is earlier, meaning for the initial prostate biopsy.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More